{"id":6916,"date":"2020-05-06T14:45:03","date_gmt":"2020-05-06T14:45:03","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/aktien\/nyemissioner\/nyemission-2020\/"},"modified":"2026-03-19T15:40:50","modified_gmt":"2026-03-19T15:40:50","slug":"nyemission-2020","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/nyemission-2020\/","title":{"rendered":"Nyemission 2020"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6916\" class=\"elementor elementor-6916 elementor-6789\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-7443b8a{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-7443b8a e-flex e-con-boxed e-con e-parent\" data-id=\"7443b8a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-32e717e{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-32e717e e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"32e717e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9d0d473 elementor-widget elementor-widget-heading\" data-id=\"9d0d473\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Nyemission <br><span style=\"color: var(--color-orange)\">2020<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5df5600 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"5df5600\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-6df52d9{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-6df52d9 e-con-full e-flex e-con e-child\" data-id=\"6df52d9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7c5e4b5 elementor-widget elementor-widget-text-editor\" data-id=\"7c5e4b5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides har genomf\u00f6rt en riktad nyemission om cirka 1 414 miljoner kronor (144 MUSD)<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8fc6bef elementor-widget elementor-widget-text-editor\" data-id=\"8fc6bef\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>6 maj 2020 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB (publ) offentligg\u00f6r h\u00e4rmed att Bolaget framg\u00e5ngsrikt har genomf\u00f6rt en riktad nyemission som inbringar en bruttolikvid om cirka 1 414 miljoner kronor (144 MUSD).<\/p><p>Styrelsen f\u00f6r Oncopeptides har, med st\u00f6d av bemyndigandet fr\u00e5n extra bolagsst\u00e4mman den 17 december 2019, och i enlighet med vad som indikerades i Bolagets pressmeddelande den 5 maj 2020, beslutat om en riktad nyemission av 12 295 000 aktier (de \u201dNya Aktierna\u201d) till en teckningskurs om 115 kronor per aktie (\u201dNyemissionen\u201d), vilket inneb\u00e4r att Bolaget kommer att tillf\u00f6ras en bruttolikvid om cirka 1 414 miljoner kronor (cirka 144 miljoner USD). P\u00e5 grund av h\u00f6g efterfr\u00e5gan \u00f6kades bruttolikviden i Nyemissionen fr\u00e5n beloppet om 1 180 miljoner kronor som indikerades i Bolagets pressmeddelande den 5 maj 2020. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a68e389 elementor-widget elementor-widget-button\" data-id=\"a68e389\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/press-releases\/oncopeptides-ab-oncopeptides-has-completed-a-directed-share-issue-raising-approximately-sek-1414-million-usd-144-m\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6b2f74b dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"6b2f74b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-58d5792{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-58d5792 e-con-full e-flex e-con e-child\" data-id=\"58d5792\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5a5e871 elementor-widget elementor-widget-text-editor\" data-id=\"5a5e871\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides avser att genomf\u00f6ra en riktad nyemission<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2de3e49 elementor-widget elementor-widget-text-editor\" data-id=\"2de3e49\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t5 maj 2020 \u2013 Regulatoriskt pressmeddelande\n\nOncopeptides AB (publ) offentligg\u00f6r idag avsikten att genomf\u00f6ra en riktad nyemission till svenska och internationella institutionella investerare (\u201cNyemissionen\u201d). Bolaget har anlitat Carnegie, DNB Markets, Jefferies, Cowen och Kempen &amp; Co som joint bookrunners (\u201dJoint Bookrunners\u201d) i samband med Nyemissionen. \n\nTeckningskursen och antalet nyemitterade aktier i Nyemissionen kommer att fastst\u00e4llas genom ett accelererat bookbuilding-f\u00f6rfarande. Avsikten \u00e4r att Nyemissionen ska inbringa en bruttolikvid om cirka 1 180 miljoner SEK (120 miljoner USD). Bookbuilding-f\u00f6rfarandet kommer att p\u00e5b\u00f6rjas omedelbart efter offentligg\u00f6randet av detta pressmeddelande.  \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e661881 elementor-widget elementor-widget-button\" data-id=\"e661881\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/press-releases\/oncopeptides-ab-oncopeptides-intends-to-carry-out-a-directed-share-issue-2\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6916","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6916\/revisions"}],"predecessor-version":[{"id":6917,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6916\/revisions\/6917"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=6916"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=6916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}